quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·128d
PRRelease
Soligenix Inc. logo

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

SNGX· Soligenix Inc.
Health Care
Original source

Companies

  • SNGX
    Soligenix Inc.
    Health Care

Related

  • SEC21d
    SEC Form EFFECT filed by Soligenix Inc.
  • SEC21d
    SEC Form EFFECT filed by Soligenix Inc.
  • SEC21d
    SEC Form EFFECT filed by Soligenix Inc.
  • SEC21d
    SEC Form EFFECT filed by Soligenix Inc.
  • PR22d
    Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
  • SEC23d
    SEC Form POS AM filed by Soligenix Inc.
  • SEC23d
    SEC Form POS AM filed by Soligenix Inc.
  • SEC23d
    SEC Form POS AM filed by Soligenix Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022